Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

amgen europe b.v. - tsinakaltseetvesinikkloriid - hypercalcemia; parathyroid neoplasms; hyperparathyroidism - kaltsiumi homöostaas - teisese hyperparathyroidismadultstreatment teisese hyperparathyroidism (hpt) täiskasvanud patsientidel, kellel on lõpp-staadiumis neeruhaigusega (esrd) hooldus dialüüs ravi. lastel populationtreatment teisese hyperparathyroidism (hpt) lastele vanuses 3 aastat ja vanemad koos lõpp-staadiumis neeruhaigusega (esrd) hooldus dialüüs ravi kellele sekundaarse hpt ei ole piisavalt ohjatud, kellel standardne ravi ravi. mimpara võib kasutada osana ravi raviskeemi sealhulgas fosfaat sideained ja/või vitamiin d steroolid, kui see on asjakohane. kõrvalkilpnäärmehormoone kartsinoomi ja primaarse hyperparathyroidism täiskasvanutel. vähendamine hypercalcaemia täiskasvanud patsientidel, kellel on:kõrvalkilpnäärmehormoone kartsinoom;primaarse hpt, kellele parathyroidectomy oleks märgitud alusel seerumi kaltsiumi taset (nagu on määratletud vastavate ravijuhiste), kuid kelle parathyroidectomy on kliiniliselt asjakohane või on vastunäidustatud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - topotekaan - uterine cervical neoplasms; small cell lung carcinoma - muud antineoplastilised ained - topotekaani monoteraapia on näidustatud retsidiveerunud väikerakk-kopsuvähi (sclc) patsientide raviks, kelle puhul ei peeta esmavaliku raviskeemi korduvat ravi sobivaks. topotecan koos cisplatin on näidustatud patsientidele, kellel kartsinoomi, emakakaela korduvad pärast kiiritusravi ja patsientidel ivb staadiumi haigus. patsientidel, kellel eelnev kokkupuude cisplatin nõuavad pidevat ravi-vaba intervalliga, et õigustada ravi kombinatsioon.

Euroopa Liit - eesti - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Eesti - eesti - Ravimiamet

teva gmbh - glatirameeratsetaat - süstelahus süstlis - 20mg 1ml 1ml 30tk; 20mg 1ml 1ml 7tk; 20mg 1ml 1ml 28tk; 20mg 1ml 1ml 90tk

Eesti - eesti - Ravimiamet

bayer ag - drospirenoon+östradiool - õhukese polümeerikattega tablett - 2mg+1mg 84tk; 2mg+1mg 28tk

Eesti - eesti - Ravimiamet

teva gmbh - glatirameeratsetaat - süstelahus süstlis - 40mg 1ml 1ml 12tk; 40mg 1ml 1ml 36tk

Eesti - eesti - Ravimiamet

zentiva k.s. - glatirameeratsetaat - süstelahus süstlis - 40mg 1ml 1ml 12tk; 40mg 1ml 1ml 3tk; 40mg 1ml 1ml 36tk

Eesti - eesti - Ravimiamet

zentiva k.s. - glatirameeratsetaat - süstelahus süstlis - 20mg 1ml 1ml 7tk; 20mg 1ml 1ml 28tk; 20mg 1ml 1ml 30tk; 20mg 1ml 1ml 90tk